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BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal
cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor
receptor signal transduction pathway.
METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n¼43) and on metastatic
(n¼24) sites in CRC patients treated with cetuximab.
RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive
disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; Po0.05), PFS (0.8 vs 8.2 months; Po0.001) and OS (2.9 vs
14.2 months; Po0.001).
CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.
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Among patients with advanced colorectal cancer (CRC), a small
subgroup seems to benefit from the epidermal growth factor
receptor (EGFR) inhibitor, cetuximab (Cunningham et al, 2004;
Saltz et al, 2004). An optimal response to EGFR inhibitors requires
the EGFR-activated intracellular signal transduction pathway to
be intact (Ciardiello and Tortora, 2008). Epidermal growth factor
receptor-dependent cancer cells may escape from cetuximab
inhibition by using alternative pathways (Viloria-Petit et al,
2001) or through a continuous activation of downstream
intracellular signalling (Bianco et al, 2003).
Phosphatase and tensin homologue deleted in chromosome
10 (PTEN) is an important tumour-suppressor gene that negatively
regulates Akt activities (Stambolic et al, 1998). Loss of PTEN
function has been reported in CRC (Thomas and Grandis, 2004)
and may represent one of the resistance mechanisms interfer-
ing with the response to EGFR antagonists by dissociating
EGFR inhibition from the downstream phosphatdylinositol
3-kinase/Akt pathway (Baselga, 2001).
MATERIALS AND METHODS
Our experience refers to 50 mCRC patients submitted both
to the evaluation of PTEN and pAKT expression by indirect
immunofluorescence (IFI) and to PTEN and EGFR gene copy
number assessments by fluorescence in situ hybridisation (FISH).
Phosphatase and tensin homologue deleted in chromosome
10 and pAKT IFI assessments were performed on 4-mm-thick
tissue sections of paraffin-embedded specimens by using a
PTEN rabbit monoclonal antibody (Millipore, Billerica, MA,
USA) and a pAKT (Ser 473) rabbit monoclonal antibody
(Cell Signaling Technology, Beverly, MA, USA), respectively,
followed by FITC-conjugated specific secondary antibody
(Sigma-Aldrich Corp., St Louis, MO, USA). Indirect immunofluo-
rescence-positive tumour cells were recognised by bisbenzimide
(Hoechst 33258) (Sigma-Aldrich Corp.) and images were obtai-
ned by fluorescent microscopy (Olympus BX41, Olympus, Inc.,
Melville, NY, USA). Fluorescence intensity was scored as absent,
weak, moderate and strong. For both PTEN and pAKT, the
percentage of cells expressing antigens was determined by
evaluating the number of positive cells in a field with reference
to the total number of cells in that field. Samples with an absent or
weak expression in o10% of cells were considered as negative.
Phosphatase and tensin homologue deleted in chromosome 10
copy number status assessment was performed on 4-mm paraffin-
embedded sections using a hybridisation solution containing both
a rhodamine-conjugated probe that is specific for the PTEN locus
on chromosome 10q23.21 and a FITC-conjugated control probe
specific for 10p11.1–q11.1 (LSI PTEN/CEP10 – Vysis Inc., Down-
ers Grove, IL, USA). Nuclei were counterstained with DAPI
for viewing on an Olympus MX60 fluorescence microscope
with a 100-W mercury lamp. Separate narrow band pass filters
were used for the detection of Spectrum Orange, Spectrum Green
and DAPI. Hemizygous deletion of PTEN was defined as 420% of
tumour nuclei containing one PTEN locus signal and by the
presence of CEP10 signals. Homozygous deletion of PTEN was
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sexhibited by the simultaneous lack of both PTEN locus signals
and by the presence of control signals in 430% of cells
(Yoshimoto et al, 2007).
Epidermal growth factor receptor FISH was performed using
the LSI EGFR Spectrum Orange/CEP 7 Spectrum Green probe
set (Vysis), and counterstaining and viewing were performed
as described above for the PTEN gene. An increased EGFR gene
copy number was defined as the presence of three or more signals
per nucleus (Moroni et al, 2005).
RESULTS
Of the patients, 80% (40 out of 50) received X3 lines of chemo-
therapy. A total of 36 patients were treated with cetuximab
and irinotecan and 14 with cetuximab and oxaliplatin. Patients
who obtained a partial response (PR) or a stable disease (SD) were
defined as responders. In all, 12 patients (24%) experienced PR,
14 (28%) experienced SD and 24 (48%) experienced a progres-
sive disease (PD). At a median follow-up of 23 months, 49 patients
(98%) progressed and 40 (80%) died. In the whole group, median
PFS and OS were 4.0 and 9.3 months, respectively.
Phosphatase and tensin homologue deleted in chromosome
10-positive staining was mainly localised to the cytoplasm of
CRC cells. An example of a PTEN-positive CRC is shown in
Figure 1a and a PTEN-negative CRC in Figure 1b. In all, 5 out of 43
(12%) of the evaluable primary tumours, and 4 out of 24 (17%) of
the metastases were PTEN IFI negative. The loss of PTEN
expression tested on metastatic sites was negatively associated
with response (100% PD in PTEN-negative cases vs 30% PD in
PTEN-positive cases; Po0.05) (Table 1), PFS (0.8 vs 8.2 months;
Po0.001) and OS (2.9 vs 14.2 months; Po0.001). Of the paired
primary tumours and matched metastases, 25% (5 out of 20)
were discordant for PTEN expression. Hemozygous deletion
of PTEN was present in 33% (15 out of 45) of primary tumours
and all of these had an absent or weak protein expression
(Po0.005). The PTEN FISH assessed on primary tumour
was neither predictive nor prognostic. No correlation was found
between PTEN FISH and PTEN expression on metastatic
sites probably because of the low number of cases (n¼17).
pAKT was not predictive of response, PFS and OS, neither was
EGFR.
DISCUSSION
According to the data obtained by Loupakis et al (2009), who
evaluated PTEN expression by IHC, we found a significant
correlation between PTEN tested by IFI on metastatic sites and
response and PFS. Moreover, in our data, PTEN also predicted OS.
However, given the small number of cases, our results may deserve
further validation in a wider cohort.
In our series, 25% (5 out of 20) of cases showed a PTEN primary
tumour vs metastasis discordance. As recently reported by
Molinari et al (2009), our observation confirms that primary
CRC and paired metastasis may exhibit a difference with respect to
the EGFR pathway; therefore, the analysis of metastatic sites
should be considered, given that PTEN assessed on primary
tumour might incompletely predict the response.
Epidermal growth factor receptor protein expression is no
longer considered as selection criteria for cetuximab sensitivity
(Cunningham et al, 2004; Saltz et al, 2004; Chung et al, 2005), and
the mechanism of cetuximab’s anti-tumour activity remains a
fundamental question to be clearly addressed. A possible
functional interaction of PTEN activity with EGFR tyrosine kinase
signalling and a potential role for PTEN in the anti-tumour activity
of cetuximab could be hypothesised.
50 µm
50 µm
Figure 1 PTEN protein expression by immunofluorescence in CRC
cells. (A) Positive (green) cytoplasmic staining. (B) Negative staining. Scale
bar¼50mm.
Table 1 PTEN IFI on primary tumours and metastases and response to
treatment
Primary tumours
(n¼43)
Metastases
(n¼24)
Responders
n (%)
Non-
responders
n (%) P-value
Responders
n (%)
Non-
responders
n (%) P-value
PTEN negative 1 (20) 4 (80) 0 (0) 4 (100)
PTEN positive 21 (55) 17 (45) 0.185 14 (70) 6 (30) 0.02
Abbreviations: PTEN¼phosphatase and tensin homologue deleted in chromosome
10; IFI¼indirect immunofluorescence.
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